CAMBRIDGE, Mass.--(BUSINESS WIRE)--Imara Inc. today announced it will report additional preclinical and Phase 1 clinical data from the company’s lead compound, IMR-687, a once-daily, oral therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback